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ABSTRACT
Introduction: Dark adaptation (DA) has been
proposed as a possible functional biomarker for
age-related macular degeneration (AMD). In
this systematic review we aim to evaluate cur-
rent methodology used to assess DA in people
with AMD, the evidence of precision in detect-
ing the onset and progression of AMD, and the
relationship between DA and other functional
and structural measures.
Methods: MEDLINE, EMBASE, CINAHL, AMED,
PsycINFO, PsycARTICLES were searched for
studies published between January 2006 and
January 2020 that assessed DA in people with
AMD. Details of eligible studies including study
design, characteristics of study population and
outcomes were recorded. All included studies
underwent quality appraisal using approved
critical appraisal tools. This systematic review
follows PRISMA guidelines (PROSPERO regis-
tration number: CRD42019129486).
Results: Forty-eight studies were eligible for
inclusion, reporting a variety of instruments
and protocols to assess different DA parameters.
Twenty of these studies used the AdaptDx
(MacuLogix, Hummelstown, PA, USA) instru-
ment and assessed rod-intercept time (RIT).
Most of these reported that RIT was delayed in
people with AMD and this delay worsened with
AMD severity. Four studies, involving 533 par-
ticipants, reported estimates of diagnostic per-
formance of AdaptDx to separate people with
AMD from visually healthy controls. DA has
been compared to other measures of visual
function, patient-reported outcome measures
(PROMs) and structural measures. Ten studies
specifically considered evidence that the pres-
ence of certain structural abnormalities was
associated with impaired DA in AMD.
Conclusions: This systematic review indicates
overwhelming evidence of reasonable quality for
an association between impaired DA and AMD.
Data on the repeatability and reproducibility of
DA measurement are sparse. There is evidence
that structural abnormalities such as reticular
drusen are associated with prolongation of DA
time. Fewer studies have explored an association
between DA and other measures of visual func-
tion or PROMs. We found no studies that had
comparedDAwithperformance-basedmeasures.
Keywords: AdaptDx; Age-related macular
degeneration; AMD; Dark adaptation; Dark
adaptometer; Rod-intercept time; Systematic
literature review
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Key Summary Points
Dark adaptation has been proposed as a
possible functional biomarker for age-
related macular degeneration (AMD).
The last review on the measurement of
dark adaptation in people with AMD was
performed in 2006, and since then, new
studies have been published and new
instruments to measure dark adaptation
have been created.
This systematic review found
overwhelming evidence in the literature
of an association between impaired dark
adaptation and AMD.
Further study is needed to investigate its
discriminatory power to better
differentiate early-stage AMD and
normative macular ageing, along with
additional data on repeatability and
reproducibility of measurement.
There is evidence that structural
abnormalities such as reticular drusen are
associated with a prolongation of dark
adaptation time, while few studies have
explored an association between dark
adaptation and other measures of visual
function or patient-reported outcome
measures.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13353146.
INTRODUCTION
Age-related macular degeneration (AMD) is the
primary cause of loss of sight in ageing
populations of the developed world [1]. Cur-
rently, effective treatment can slow the pro-
gression of neovascular (wet) AMD, and
extensive research is underway to develop
effective interventions for non-neovascular
(dry) AMD [2, 3]. It is therefore important to
identify AMD in its earliest stages so disease
progression can be potentially delayed. In order
to reduce the duration and costs associated with
trials for new treatments of AMD, sensitive
biomarkers for disease progression are also
required [4]. The retinal pigment epithelium
(RPE) is believed to be the fulcrum of the AMD
disease process [5], whilst the provision of 11-cis
retinal from the RPE to the photoreceptors is
the limiting factor in the rate of visual pigment
regeneration in photoreceptors. Therefore, dark
adaptation (DA) has been proposed as a func-
tional biomarker for AMD onset and progres-
sion [6].
The term ‘dark adaptation’ describes the
recovery of visual sensitivity to light stimuli in a
dark environment after light exposure has
bleached a significant proportion of visual pig-
ment. DA is determined in part by the rate
(speed) of visual pigment regeneration in pho-
toreceptors, which is also dependent on the
functional integrity of the choroidal circula-
tion, Bruch’s membrane and, crucially, the RPE
[7]. Abnormal DA manifests in reduced rates of
recovery of rod and cone sensitivity, delayed
rod-cone break (RCB) and/or an increased pho-
toreceptor absolute threshold [6].
Measuring DA can likely be traced back to
the nineteenth century, when Aubert [8] first
described DA using the glow of a just visible
platinum wire as a stimulus. Developments
have since been made, from the early DA curves
plotted by Hecht, Haig and Chase [9] to the
landmark mathematical model of DA by Lamb
and Pugh [7]. More recently, dark adaptometers
have been designed for clinical use, with
instruments designed to assess DA in conditions
like AMD.
It has been suggested that delayed DA may
manifest before the appearance of clinical fea-
tures of AMD such as drusen and focal pig-
mentary changes [10, 11]. Indeed, DA has been
reported to be a diagnostic indicator of AMD
[12, 13]. Time taken for DA to occur has also
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been shown to progressively increase with
increasing severity of AMD, suggesting it has
potential not only as a diagnostic tool but also
as a biomarker for disease progression [14–16].
The most recent systematic review consider-
ing DA assessment in people with AMD was
published as part of a wider review on visual
function tests in 2006 [17]. Since then, new
studies on DA measurement have been pub-
lished. Moreover, some instruments for mea-
suring DA have become commercially and
widely available, such as the AdaptDx adap-
tometer (MacuLogix, Hummelstown, PA, USA)
[12, 13]. DA is also one of the candidate
biomarkers being examined by a large multi-
centre longitudinal study aiming to find better
ways of detecting progression in AMD [4].
In this systematic review we aim to evaluate
current methodology used to assess DA in peo-
ple with AMD. The review specifically examines
the evidence of diagnostic precision of these
methods in detecting the onset of AMD, as well
as the sensitivity to disease progression. The
report is focused on the AdaptDx instrument as
the device which is used most widely in the
recent literature. We also explore evidence of
associations between DA and functional vision
measures, structural measures, patient-reported
outcome measures (PROMs) and outcomes from
performance-based studies (involving assess-
ment of visually guided tasks such as face
recognition or mobility assessments). This sys-
tematic review follows the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines, and a detailed protocol
has been published on PROSPERO (registration
number: CRD42019129486).
METHODS
Eligibility Criteria for Considering Studies
for this Systematic Review
To be eligible for inclusion, studies had to be:
(1) published in the English language; (2) dated
from January 2006 to January 2020 to include
studies following the review by Hogg and
Chakravarthy [17]; (3) include participants with
AMD (of any stage); and (4) include a dynamic
measurement of rod and/or cone DA. Studies
were excluded if they were review articles, let-
ters to the editor, published protocols or con-
ference abstracts.
Search Methods for Identifying Studies
The following databases were searched:
CINAHL, MEDLINE, PsycINFO and Psy-
cARTICLES (via EBSCO) and EMBASE and
AMED (via OVID) for publications published
between 01/01/2006 and 27/01/2020. An
indicative list of search terms and the search
query used is provided in Table S1 (see elec-
tronic supplementary material for details). Key
terms regarding AMD, DA and dynamic photo-
stress testing were used. The reference lists of
the included literature were examined as a fur-
ther source of relevant studies. Covidence soft-
ware [18] (Veritas Health Innovation, https://
www.covidence.org) was used for extraction,
organisation and screening of the literature.
Study Selection
Duplicates were automatically removed by
Covidence software [18]. Two authors (BEH and
DJT) independently assessed for eligibility for
inclusion through screening titles and abstracts.
The same two authors then independently read
the full texts of potential eligible studies with
any disagreements about inclusion resolved
through discussion and then arbitration by a
third author (AMB).
Data Collection and Risk of Bias
Assessment
Two authors (BEH and DJT) independently
evaluated the quality of the included studies.
The Critical Appraisal Skill programme tool [19]
(CASP; Critical Appraisal Skills Programme.
https://casp-uk.net/) was used to assess cohort,
case–control and randomised controlled trial
study designs. The Joanna Briggs Institute crit-
ical appraisal tool [20] (JBI; Joanna Briggs Insti-
tute, https://joannabriggs.org) was used to
assess cross-sectional and case-series design
types. These tools are recommended by the UK
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National Institute for Health and Care Excel-
lence [21] (NICE; National Institute for Health
and Care Excellence, https://www.nice.org.uk/)
guidelines. The summarised quality appraisal
results are shown in Table S2 (see electronic
supplementary material for details).
Data Synthesis and Analysis
Study characteristics were extracted into a data
synthesis table (Table S3; see electronic supple-
mentary material for details). A meta-analysis
was not appropriate given the range of stimulus
and bleach parameters employed by different
studies. Data were analysed based upon repor-
ted DA and/or photostress procedure (Table S4;
see electronic supplementary materials), diag-
nostic accuracy and repeatability measures
reported (Table S5; see electronic supplemen-
tary materials) and reported vision and struc-
tural outcome measures compared to
parameters of DA (Table S6; see electronic sup-
plementary materials). Data on reported out-
come measures compared to parameters of DA,
unrelated to vision, were also recorded but not
analysed (Table S7; see electronic supplemen-
tary materials). This article is based on previ-
ously conducted studies and does not contain
any studies with human participants or animals
performed by any of the authors.
RESULTS
The search of bibliographic databases performed
on 27th January 2020 identified 512 publica-
tions. During this screening procedure, most
studies (n = 397) were excluded, principally for
not reporting measures of dynamic DA or not
including a study population with people who
had AMD. Sixty-seven full texts screened were
removed primarily because their format was
ineligible for this systematic review (e.g. con-
ference abstract) resulting in 48 papers deemed
appropriate for the final review process (Fig. 1).
The 48 included publications were subjected
to quality appraisal. The CASP tool was used for
cohort (n = 4), case–control (n = 20) and ran-
domised controlled trial (n = 4) study designs.
The JBI tool was used for cross-sectional (n = 17)
and case studies (n = 3). The grading of all
papers can be found in Table S2 (see electronic
supplementary material for details). The main
source of bias was selection bias, whereby most
observational studies did not explicitly report
their recruitment strategies. Moreover, some
studies were conducted on small sample sizes
that could lead to systematic over- or under-
estimation of effects. In addition, a large per-
centage of the studies did not report standard
deviations (SD) or confidence intervals (CI) for
the DA parameter, which made it difficult to
judge the precision of the results. These factors
were considered when analysing the results.
What follows is a short narrative summary of
the main findings of the 48 studies included in
this systematic review, with a focus on the 21
studies that used the AdaptDx and AdaptRx
devices (Apeliotus Technologies, Atlanta, GA,
USA). The other 27 studies used myriad lab-
based dark adaptometers, dynamic photostress
tests devices and the occasional commercially
available instrument like the Roland Consult
Dark Adaptometer (RCDA; Roland Consult
GmbH, Germany) [22]. Full details about each
study are in Tables S3–7 (see electronic supple-
mentary materials for details).
AdaptDx: Testing Procedures
AdaptDx and AdaptRx were used to measure
rod-mediated DA in 21 studies
[10, 12–14, 16, 23–38]. The AdaptRx method-
ology appeared identical to the AdaptDx and
was reported once in the reviewed literature by
Flamendorf et al. [23].
The most frequently reported DA parameter
was rod-intercept time (RIT) (20 out of 21
studies) [10, 12–14, 16, 23–36, 38], an estimate
of the time duration for the rods to recover to
an established criterion sensitivity (i.e.
5 9 10-3 cd/m2) after focal bleaching [13].
Clark et al. [37] was the only study which fitted
AdaptDx threshold data with a biological model
of rod-mediated DA and analysed the slopes of
the second and third components of recovery,
final threshold recorded during the 20 min test
period, and ‘mean threshold’ (the average of all
thresholds after 300-s post-bleach).
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There were different approaches to bleaching
magnitude and target position reported in the
literature that varied depending upon the aim
of the study. For example, the most commonly
reported bleaching procedure in these studies
was an 82–83% photoreceptor bleach using a
flash of 5.8 9 104 scotopic cds/m2 intensity or
equivalent for 0.25 ms [10, 13, 14, 23, 27–31,
33, 36, 37] (12 out of 21 studies). This bleaching
light has been reported by Jackson and Edwards
[13] to be sufficient in magnitude to demon-
strate impaired DA in people with early AMD
when using the 20 min duration AdaptDx pro-
tocol. Another reported bleaching procedure in
the literature was a 76% photoreceptor bleach
using a flash of 1.8 9 104 scotopic cds/m2
intensity for 0.8 ms [12, 16, 24–26, 32,
34–36, 38] (10 out of 21 studies), which has
been also reported as sufficient in highlighting
the AMD-related DA impairment [12]. Chen
et al. [36] reportedly used both an 82% and a
modified 76% bleaching procedure. Only a
handful of studies explicitly reported the
wavelength of the bleach as 505 nm (7 out of 21
studies) [12, 24–26, 32, 34, 38].
The most commonly reported testing loca-
tion of the bleaching procedures and subse-
quent location of threshold measurements was
centred at 5 on the inferior vertical meridian
(19 out of 21 studies) [10, 12–14, 23–34, 36–38],
which is consistent with evidence of preferen-
tial damage to the parafoveal retina in the ear-
liest stages of AMD [39, 40]. Three studies
reported a test location of 11/12 eccentricity
Fig. 1 Study selection process
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[16, 35, 36]. In two of these cases, both 5 and
12 locations were evaluated [35, 36]. Binns
et al. [35] recently compared different bleaching
protocols (65%, 70% and 76% photoreceptor
bleach at either 5 or 12 inferior field). It was
concluded that 76% bleach at 12 eccentricity
allowed for separation between the groups in
the sample and reduced recovery time to under
20 min, compared to more extended recovery
times in the 5 location [35].
The AdaptDx has a threshold stimulus size of
1.7–2.0 with a wavelength of 500–505 nm
[10, 12–14, 16, 23–38], centred on a bleached
area subtending 4. Eight studies reported that
the stimulus was first presented 15 s after
bleaching onset [10, 16, 27–30, 35, 37] while
others reported that it started immediately after
bleaching [24, 34]. The most frequently repor-
ted maximum test time (or cut-off time) was 20
min [10, 12, 13, 24–26, 28–32, 37, 38] (13 out of
21 studies) followed by 40 min
[16, 23, 27, 33, 36] (5 out of 21 studies), 45 min
[14, 34] (2 out of 21 studies) and 30 min [35] (1
out of 21 studies). For the rapid procedure, the
DA functions were truncated to 6.5 min [12].
Twelve studies assigned the participant an
RIT value (in most cases, the cut-off time) if
they failed to recover within the duration of the
test [13, 14, 23–27, 33–36, 38]. It was not clearly
reported by six studies what this value was set to
if the participant surpassed the cut-off time
[10, 28–31, 37]. Two studies appeared to use an
estimated recovery time based on the observed
trend up to the maximum recording time, but
when the parameter was unable to be extrapo-
lated, it was again set to the experimental cut-
off time [12, 32]. Conversely, Owsley et al. [16]
set the value to ‘indeterminate’ rather than
assign an estimated RIT.
AdaptDx: Diagnostic Precision,
Repeatability and Longitudinal Studies
Three studies specifically reported estimates of
diagnostic performance (sensitivity and speci-
ficity) of AdaptDx to separate people with AMD
from visually healthy controls [12, 13, 35]. Only
one of these studies had this as its primary aim
[12]. A fourth reported the prognostic
performance of the test at identifying healthy
individuals who would develop AMD within
3 years of baseline testing [29].
Jackson and Edwards [13] introduced the
AdaptDx 20 min protocol in a study of controls
[n = 17, eight young participants (mean age
32.6 years) and nine old participants (mean age
73.1 years)] and participants with AMD
(n = 17). The threshold for being test negative
was B 12.5 min; this yielded a sensitivity of
88% and specificity of 100%. Notably, nine
participants with AMD [incidentally, the whole
of the intermediate (iAMD) and late AMD
cohort] were unable to complete the test so
were assigned an RIT of 20 min. The small
sample size yielded wide CIs and is considered
insufficient to allow analysis of the true diag-
nostic precision of the 20 min procedure [13].
Jackson et al. [12] reported results from a
prospectively planned cross-sectional study (at
three centres) of people with AMD (n = 127)
and visually healthy people (n = 21). The refer-
ence standard was clinical examination and
grading of colour fundus photographs (CFP).
The AdaptDx rapid protocol was the index test
with RIT of B 6.5 min as the threshold for being
test negative; this yielded a sensitivity of 91%
and a specificity of 91%. Fourteen people
reportedly could not do the examination; this is
a noteworthy bias, because the authors failed to
include this in their estimates of diagnostic
precision. Moreover, the small sample of con-
trols meant that the lower bound of the 95% CI
for specificity was * 70%, but this was not
reported in the abstract. Further examination
revealed that sensitivity was reduced (81%) in
people investigators classified as having early
AMD. The groups were not age-related (controls
were mean * 8 years younger) and this is
another limitation of the results [12].
Binns et al. [35] primarily aimed to deter-
mine optimal test conditions for evaluating DA
in iAMD using the AdaptDx. The authors used
estimates of diagnostic precision (area under the
receiver operating characteristics [AuROC]
curves) to conclude that a 76% bleach at 5
eccentricity provided ‘optimal’ separation
between AMD and controls; however, this was
at the expense of a long recording duration. An
alternative test location was suggested at 12 to
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provide adequate diagnostic accuracy whilst
reducing recording time by more than 50%. The
authors reported estimates of diagnostic preci-
sion at different cut-offs (sensitivity and speci-
ficity of 89% and 63%, respectively, for the
optimal condition, for example), but the small
sample size (n = 16 people with AMD and
n = 10 controls) was insufficient to allow eval-
uation of the true diagnostic precision of the
procedure [35].
In a well-designed cohort study, albeit at a
single centre, Owsley et al. [29] primarily aimed
to examine whether slowed RIT (measured with
an extended AdaptDx protocol) in adults with
normal macular health (n = 325) at baseline was
associated with the incidence of AMD 3 years
later. After adjustment for age and smoking,
those with abnormal DA (defined as RIT C 12.3
min) at baseline were approximately twice as
likely to have AMD in that eye by the time of
the follow-up visit as those who had normal DA
at baseline. The purpose of this study was not to
evaluate the diagnostic precision, but the
authors reported sensitivity and specificity of
33% and 83%, respectively, for incident AMD in
patients in normal macular health at baseline
[29].
Only one paper explicitly provided data
about the repeatability of DA measurement
with the AdaptDx. Flamendorf et al. [23], using
the AdaptRx, conducted a cross-sectional, sin-
gle-centre study of participants ([50 years)
with and without AMD (n = 116). Patients were
stratified by fundus features, with 36% having
‘no large drusen’. The authors primarily
demonstrated that RIT was associated with age,
AMD severity and subfoveal choroidal thick-
ness. A subsample of participants (n = 87)
underwent repeat examination * 1 week later,
and the authors reported a mean (± SD) RIT
difference of 0.02 ± 2.26 min; this translates to
95% limits of agreement of -4.41 to 4.46 min,
which is quite wide given the average RIT. The
authors claimed that repeatability did not differ
significantly between AMD groups but it is not
explicitly clear how they analysed this. The
authors did provide a Bland–Altman graph
showing the differences in test–retest variability
which did not seem to increase with worse RIT.
Yet on inspection, it appeared those
participants recording a RIT below 10 min had
better RIT repeatability [23].
There is clear evidence for an association
between delayed DA and presence of AMD.
However, we only identified five longitudinal
studies assessing DA measurements from
AdaptDx over time [14, 16, 29, 30, 36].
Jackson et al. [14] prospectively collected DA,
visual acuity (VA) and CFP at baseline and at 6
months and 12 months in people with AMD
(n = 26). The investigators observed worsening
of DA in five participants in 12 months of
observation, despite seemingly stable VA and
fundus appearance. The study was limited by
the small sample size and had a small control
group who were not age-related (n = 6). Four
AMD participants exhibited large changes in DA
at 6 months, which was inconsistent with their
DA at 12 months [14].
The previously mentioned cohort study
reported by Owsley et al. [29] focused on elderly
people without AMD and showed delayed DA at
baseline was associated with development of
AMD at 3 years. Owsley et al. [30] reiterated this
finding in another paper comparing the associ-
ation of impaired visual function to AMD inci-
dence 3 years later (using the previously
reported DA results for 363 eyes) [29]. Impaired
mesopic acuity was found to have a weaker
association to AMD incidence compared to DA
[30]. The same research group was responsible
for another 2 year longitudinal study reporting
on eyes with iAMD (n = 30) and measurable
RITs [16]. This paper reported that rod-mediated
DA slowed in iAMD over 2 years in most eyes
and gave useful data on the expected average
RIT change over time, but concluded that there
was wide variability both in RIT at baseline, and
in the extent to which it increased over 24
months.
Chen et al. [36] conducted a notable longi-
tudinal study of changes in RIT in people with a
range of AMD severities (n = 77) over 4 years;
they indicated that decline in DA accelerated in
eyes with greater AMD severity and especially in
eyes that had subretinal drusenoid deposits
(SDD) both at baseline and at 4 years (see
below).
Ophthalmol Ther (2021) 10:21–38 27
AdaptDx: Relationship with Other
Measures
The secondary aim of this systematic review was
to assess the relationship of DA measures with
other factors. The latter include measures of
visual function, structural measures from pho-
tographs or images, PROMs and potentially
performance-based metrics within the litera-
ture. For this review, all factors directly (and
statistically) compared to DA parameters were
recorded for each study in their entirety
(Tables S3–7; see electronic supplementary
material for details). These were then cate-
gorised into relevant themes and are sum-
marised briefly below.
The most frequent factor directly compared
to RIT in the literature was AMD presence and
severity of AMD (19 out of 21 studies)
[10, 12–14, 16, 23, 24, 26, 27, 29–31, 33–38]. It
was generally reported by authors that a pres-
ence of AMD was associated with slowed or
‘abnormal’ RIT [10, 12–14, 16, 23, 24, 26, 27,
29, 30, 33–38] when compared to visually heal-
thy controls [10, 12–14, 23, 24, 26, 27, 29,
30, 33–38], although one cross-sectional study
found no significant difference in average RIT
between people with AMD and controls once
data were age-adjusted [31]. Most of these stud-
ies reported a difference in RIT between controls
and the AMD group as a whole [12–14, 37] or
between controls and people with iAMD/ad-
vanced AMD [23, 24, 26, 33–36, 38]. While
Cocce et al. [38] found a significant difference in
RIT between early and iAMD, only a few studies
found significant differences between those
with controls and early AMD [10] and AMD
incidence [29, 30]. For example, Owsley et al.
[29] reported that visually healthy elderly people
with abnormal DA were almost twice as likely to
have AMD in the tested eye 3 years later. Jackson
and Edwards [13] reported that the mean RIT for
people with early AMD (n = 6) was nearly twice
as slow as the mean RIT in the older control
group (n = 9), but no p values were offered.
The effect of the presence of reticular drusen,
also known as pseudodrusen or SDD, on RIT was
considered in a number of studies
[23, 24, 28, 31, 33, 36]. Overall, the results
indicated that SDD presence in people with
AMD correlated with slowed RIT
[23, 24, 28, 31, 33, 36], regardless of whether the
SDDs were in the testing location [24]. Neely
et al. [28] reported that SDD presence in con-
trols did not significantly impact RIT, while eyes
with both early AMD and SDD presence did
have markedly slower RIT. However, this asso-
ciation was lost when data were adjusted for
age. Flamendorf et al. [23] reported significantly
slowed RIT in participants with SDD presence
(n = 15), with 80% reaching the test ceiling (40
min); although it is noteworthy that the SDD
group was significantly older than the controls.
Chen et al. [36] described a key association
between SDD presence and accelerated worsen-
ing of DA in their longitudinal study. Con-
versely, peripheral classic drusen (both presence
and number) have not been found to be asso-
ciated with slowed RIT [25].
The literature indicates that other structural
abnormalities also impact on RIT. For example,
delayed RIT may appear more likely in pseu-
dophakic eyes which may have implications on
the routine clinical use of the instrument
[23, 26, 29]. Chen et al. [36] observed huge
changes in RIT across the study visits just pre-
ceding and after cataract extraction. However,
age and AMD stage are evidenced to negatively
impact this association when applied in multi-
variate analysis [26, 29] and some studies report
no significant differences for lens status [24].
Others have reported an association between
impaired DA and changes in choroidal thick-
ness [23], changes in retinal thickness (adjusted
for age and VA) [37], reticular pigmentary
changes and presence of a mottled decreased
fundus autofluorescence (FAF) pattern in the
midperipheral zone [25]. Laı́ns et al. [24] found
that structural abnormalities (such as classic
drusen, ellipsoid zone disruption and serous
pigment epithelium detachment) affected DA
when found in the testing location, even after
controlling for AMD stage and age. The level of
macular pigment was not found to correlate
with rod-mediated DA in people with AMD [34].
Sevilla et al. [31] reported that hyper-reflective
foci, lower RPE-drusen-complex volume and
greater RPE-drusen-complex abnormal thinning
volume were associated with slowed RIT. Con-
trarily, no significant differences were found
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between groups (early AMD, iAMD and con-
trols) in RPE-drusen-complex, retinal volumes,
or inner and outer retinal volumes, and when
the data were age-adjusted, group differences in
RIT were also lost [31].
Genotyping of well-defined populations is
another route to discover what might happen in
early disease stages in AMD. Mullins et al. [27]
reported a cross-sectional analysis of RIT and
genetic risk factors in people aged C 60 years
with evidence of either normal visual ageing or
AMD in one or both eyes (n = 543). A novel
association was found wherein older adults with
no evidence of AMD but who had the high-risk
age-related maculopathy susceptibility-2
(ARMS2) genotype were more likely to demon-
strate delayed RIT, but not those who had the
complement factor H (CFH) genotype, while
the presence of the CFH genotype was associ-
ated with delayed RIT in people with AMD.
Further research into understanding ARMS2
function has been suggested to be a research
priority [27].
Few studies directly compared visual func-
tion measurements with RIT (4 out of 21 stud-
ies), and results differed [23, 26, 34, 36].
Flamendorf et al. [23] and Laı́ns et al. [26] found
that best-corrected VA (BCVA) and worse eye
BCVA, respectively, correlated with delayed RIT.
In the Chen et al. [36] longitudinal study,
changes in RIT occurred over 4 years while
BCVA remained largely unchanged, with a
mean of only 1.8 letters lost. The authors sug-
gested that RIT appears to show functional loss
that BCVA cannot [36], although the study
could not exclude the effects of lens removal,
which may affect longitudinal measures of
BCVA. Beirne and McConnell [34] did not find a
relationship between RIT and VA in people with
iAMD, although it was significantly associated
with contrast sensitivity (CS). This was the only
study found in the featured AdaptDx literature
that compared CS to RIT.
Few PROMs have been directly compared to
RIT. One example includes the Low Luminance
Questionnaire (LLQ) [32, 33, 36]. Yazdanie et al.
[33] found a correlation between lower scores
on the LLQ and RIT, with the strongest associ-
ation found for the driving-related subscale.
Despite BCVA yielding a statistically significant
association with LLQ, the correlations found
were marginally weaker than those found for
RIT. Yazdanie et al. [33] specifically reported
that problems with night vision and low lumi-
nance may not be explained by traditional
metrics of visual function measured in clinic.
This correlation between the LLQ and RIT has
also been found in another study [32] and when
compared to RIT progression over time [36].
However, Thompson et al. [32] found that the
correlation between the LLQ and RIT in people
with early and iAMD was not significant once
the data were controlled for AMD severity,
speculated to be due to the lack of late-stage
AMD participants.
In addition to the medical history question-
naire used by Laı́ns et al. [26], the study also
incorporated a food frequency questionnaire
and the Rapid Assessment of Physical Activity
test. After adjusting data for age and AMD stage,
body mass index, taking AREDS supplements,
and family history of AMD were significantly
associated with delayed RIT and alcohol intake
was significantly associated with RIT C 6.5 min.
There were no studies comparing measure-
ment of RIT with performance-based measures.
Other Adaptometers and Photostress Tests
A total of 27 studies presented data collected
using devices other than the AdaptDx
[15, 22, 41–65]. This included studies evaluating
parameters of either cone adaptation
[22, 43–45, 49, 50–54, 61, 62, 64], rod adapta-
tion [55–60], or both [15, 41, 42, 46–48, 63, 65].
Nineteen of these studies reported DA data
collected using some form of dark adaptometer
[22, 42, 44–50, 53–60, 63, 65]. Six studies
reported data collected using a photostress test
protocol, whereby time is recorded for cone
function (e.g. cone threshold or VA) to return to
a specified level [43, 51, 52, 61, 62, 64]. Dim-
itrov et al. [15, 41] assessed using both tech-
niques. Eight studies used an adapted
Humphrey Visual Field Perimeter (HVFP; Carl
Zeiss Meditec, Inc, Dublin, CA, USA) [43–50]
and eight utilised an ‘in-house’ adaptometer,
with methods developed by investigators
[15, 41, 42, 61–65]. Other adaptometers,
Ophthalmol Ther (2021) 10:21–38 29
featured in more than one study, included the
Medmont Dark Adapted Chromatic perimeter
(MDAC; Medmont Pty Ltd, Melbourne, Aus-
tralia) (5 out of 27 studies) [55–59] and the
Macular Disease Detection MDD-2 device
(Health Research Science, LLC, Lighthouse Pt,
FL, USA) (2 out of 27 studies) [53, 54]. The
Scotopic Sensitivity Tester-1 (SST-1; LKC Tech-
nologies, Gaithersburg, MD, USA) [60], RCDA
[22], KOWA AS14B NightVision Tester (KOWA
Optimed, Tokyo, Japan) [51], and Eger macular
stressometer (EMS; Gulden Ophthalmics, PA,
USA) [52] were used in one study each. What
follows is a brief narrative of these papers, with
more detail in Tables S3–S7 (see electronic sup-
plementary material for details).
The most frequently reported parameters of
DA in studies that did not use the AdaptDx were
RCB (10 out of 27 studies) [41, 42, 44–48,
60, 63, 65], cone absolute threshold (9 out of 27
studies) [41, 42, 44–48, 63, 65], cone time con-
stant (8 out of 27 studies) [44–50, 65] and RIT/
rod criterion time (7 out of 27 studies)
[41, 55–59, 63]. Other parameters in the
reviewed papers included rod absolute thresh-
old (5 out of 27 studies) [41, 46–48, 63] and
‘second slope’ or rod slope (5 out of 27 studies)
[42, 46–48, 65], which refers to the second
phase of rod recovery when threshold data are
fitted with a model based on the physiological
process of DA [7].
There was a wide variation in procedures
used by these studies (see Table S3; see elec-
tronic supplementary material for details).
However, some similarities exist, such as the
stimulus used. The most frequently reported
was a 1.7–2 circular stimulus [15, 41, 46–48,
50, 55–59] with a wavelength of * 500 nm
[46–48, 55–59], similar to the threshold stimu-
lus seen in the AdaptDx. To examine cone-me-
diated DA, frequently reported stimulus
wavelengths of * 620 nm [55, 56] or 650 nm
[47, 48] were seen in the literature. Eight studies
used a threshold location of 12 eccentricity
[46–48, 55–59], seven studies used a 5.5-6
location [42, 55–59, 65], seven studies used an
3.5-4 location [15, 41, 55–59], six studies used a
foveal location [41, 44, 45, 49, 50, 63], five
studies used an 8 location [55–59] and two
studies used a 3 location [42, 65].
No cut-off times signifying the end of the DA
assessment were reported for the photostress
tests, as the nature of the examination is for the
patient to return to baseline sensitivity, which
occurs relatively quickly [43, 52, 64]. The most
often reported cut-off time for the DA procedure
was 30 min (7 out of 27 studies)
[15, 41, 45, 55, 57, 59, 63], followed by 60 min
(3 out of 27 studies) [47, 48, 65]. Four of these
studies reported that the recovery parameter
was set to the maximum test time as a censored
data point [44, 45, 58, 59, 65], similar to the
procedure followed by studies that used the
AdaptDx.
Most studies that did not use AdaptDx
demonstrated DA and photostress measure-
ments to be altered in AMD
[15, 22, 41–45, 48, 50, 55–59, 63–65]. However,
use of small cohorts and/or comparative control
groups (B 10 people) [22, 43–45, 55–58, 65]
hampered many of these studies. Two studies
suggested the techniques were not useful for
AMD [52, 60]. The following narrative focuses
on notable results of the remaining studies.
Newsome et al. [64] assessed photorecovery
in controls (n = 144) and people with ‘dry’
(non-neovascular) (n = 118) and ‘wet’ (neovas-
cular) AMD (n = 36) using an in-house photo-
stress test. Prolonged photorecovery was
evident in people with non-neovascular AMD
with geographic atrophy compared to controls,
but not if only drusen were present. Worsening
non-neovascular AMD was shown to be
accompanied by prolonged photostress recov-
ery [64].
Using the adapted HVFP, Owsley et al. [48]
reported that people with AMD (n = 83) severity
ranging from early to late compared to controls
(n = 43) exhibited a significantly longer average
rod-mediated DA, while cone-mediated DA did
not differ between groups. Conversely, Dim-
itrov et al. [15] used the same modality and
reported that people with only hard and/or
intermediate drusen demonstrated significantly
abnormal cone photostress recovery and rod-
mediated DA when compared to controls
(n = 64). However, these parameters did not
discriminate between people with different
severities of AMD [15].
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Robinson et al. [50], using an in-house sys-
tem to assess cone adaptation in controls
(n = 19) and people with AMD status varying
from early to advanced (n = 81), reported mean
differences in cone time constant between
groups. The authors speculated on the mea-
surement being a potential biomarker for AMD
[50]. Participants with early AMD (n = 50),
iAMD and contralateral neovascular AMD
reported a significant delay in mean cone tau
when reassessed 12 months later in the ALIGHT
trial [66].
Various attempts have been undertaken to
quantify the diagnostic accuracy of DA tech-
niques other than AdaptDx in identifying early
AMD. Two studies [44, 45] aimed to identify the
pre-adapting light intensity and test location
that generated the maximum separation in the
parameters of cone DA and time to RCB
between participants with early AMD and con-
trols in the minimum recording time, using a
custom built adaptometer. Sample sizes were
prohibitively small, but the authors reported
estimates of sensitivity and specificity at differ-
ent thresholds and bleach conditions.
Dimitrov et al. [63] assessed the diagnostic
capacity of rod- and cone-mediated DA param-
eters using an in-house adaptometer in small
samples of people [AMD of varying severity
(n = 27) and healthy peers (n = 22)]. Cone-me-
diated parameters gave smaller AuROC curves
than rod-mediated parameters [63]. This result
was replicated in a study in large numbers by
the same team, where rod-mediated DA was
found to have the best diagnostic capacity
(AuROC, 0.93 ± 0.016), followed by cone pho-
tostress recovery (AuROC, 0.85 ± 0.021) [41].
Tahir et al. [42] used an in-house experi-
mental adaptometer designed to present stimuli
at two inferior field locations (3 and 5.5),
measuring cone- and rod-mediated DA. AuROC
was used to justify the optimal testing proce-
dure [42]. A small number of controls (n = 15)
were used, so estimates have little value in terms
of assessing the diagnostic suitability of this
paradigm.
Few longitudinal studies were found. Rodri-
guez et al. [22] primarily demonstrated that
cone-mediated visual function recovery, mea-
sured using a RCDA, could separate a small
sample of people with early AMD (n = 12) from
visually healthy controls (n = 17) with relatively
high sensitivity and specificity ([ 85%). The
repeatability and reproducibility of the RCDA
was assessed in early AMD participants (n = 8)
and visually healthy participants (n = 4). Both
baseline cone threshold and recovery half-life
were found to have a high degree of repeata-
bility across all visits (intraclass correlation
coefficient (ICC) = 0.88; and ICC = 0.93,
respectively). RCB exhibited poor repeatability
(ICC = 0.40). A follow-up after 1 year illustrated
high reproducibility of the adaptometer (base-
line cone threshold (ICC = 0.84) and the
recovery half-life (ICC = 0.84) [22]). However,
the very small sample sizes render these data
insufficient for judging the true repeatability
and reproducibility of the adaptometer.
Tan et al. [59] evaluated longitudinal rod
function at 14 different eccentricities using the
MDAC perimeter in controls (n = 23), people
with iAMD (n = 12) and people with SDDs
(n = 13). Over 12 months, a significant decrease
in the rod recovery rate was found in the iAMD
group (at the 12 test-point alone), while no
significant changes were found in RIT across all
groups.
Wolffsohn et al. [52] used a longitudinal
study and showed that EMS photostress recov-
ery time did not predict those whose vision
decreased over the following year compared
with those among whom it remained stable.
Moreover, this was the only study, not using
AdaptDx, that compared visual function mea-
surements (near and distance VA and CS) to
rates of adaptation. However, no significant
relationships were found [52].
Measurement of DA, not using AdaptDx, and
photostress parameters have been shown to be
altered, for example, in the presence of SDD
[55–59], macular oedema [64], serous macular
detachment [64], abnormal new vessels [64] and
inner segment ellipsoid zone disruption [55].
The level of macular pigment has not been
found to correlate with photostress recovery
[61]. Furthermore, Rodrigo-Diaz et al. [65]
found that parameters of the DA curves such as
the rod-mediated second slope and the RCB
were associated with FAF changes and CFP
grading. However, only a moderate correlation
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at best was found between cone time constant
and measures from FAF and CFP grading [65].
Three studies, not using the AdaptDx, com-
pared measurement of DA directly to PROM
data. Owsley et al. [46] used measures of rod-
and cone-mediated DA to validate the newly
developed LLQ, using the adapted HVFP. DA
was assessed in participants who exhibited
normal retinal ageing (n = 41) and participants
with AMD of varying severity (n = 84). An
association was established between greater
difficulties with or emotional distress linked
with low-luminance activities and worsening
rod-mediated DA, including RCB. The highest
correlation coefficients were seen between rod-
mediated DA parameters (in particular rod
threshold, defined as the average of the last
three thresholds of the rod second slope) and
the driving subscale. However, no LLQ subscales
were associated with cone-mediated DA [46]. A
significant association between rod-mediated
DA and LLQ results was also reported by Owsley
et al. [47], who assessed the effect of a 30-day
course of retinol on DA in 104 participants. It
was found that the change from baseline to day
30 in the mobility subscale was significantly
associated with changes in the slope of the
second component of rod recovery. No such
correlations were found in cone parameters. A
non-validated questionnaire on self-reported
difficulties with glare recovery was reported by
Wolffsohn et al. [52], but no association was
found between reported self-difficulties and
EMS photostress recovery time.
The National Eye Institute Visual Function
Questionnaire (NEI VFQ) [48, 51, 61, 62],
Veterans Affairs Low Vision Visual Function
Questionnaire (VFQ-48) [49], the EuroQol-5D
Instrument (EQ-5D) [49] and Pittsburgh Sleep
Quality Index (PSQI) [49] also featured in the
literature but were not compared to DA metrics.
There are no studies comparing measure-
ment of DA with performance-based measures.
DISCUSSION
Our systematic review clearly indicates that a
delay in the measured rate of DA is associated
with the presence of AMD [10, 12–16, 22–27,
29, 30, 34–38, 41–45, 48, 50, 55–59, 63–65]; this
is our main finding. Yet the evidence for mea-
surement of DA being able to discriminate early
AMD cases from elderly controls and differen-
tiate between groups of varying AMD severity is
weaker. Selection bias, problems with experi-
mental design, poor reporting of precision of
estimates and small sample sizes seem to char-
acterise many of the studies that specifically
considered diagnostic precision of the AdaptDx.
Still, some of the studies, from the Owsley
group for example, point to adequate levels of
diagnostic precision [29] and one well-designed
cohort study indicates that DA becomes
impaired in some eyes with iAMD over time
[16]. Even here, there was wide variability in
measurement of DA (RIT) at baseline and in the
extent to which it increased over 24 months.
We conclude that more longitudinal studies are
required to test whether a measure of DA is truly
a biomarker for changes in AMD severity.
The most common method used to assess DA
in people with AMD was measuring RIT using
the AdaptDx adaptometer [10, 12–14, 16,
23–38]. Since the protocol was first introduced
by Jackson and Edwards [13], the AdaptDx has
been used frequently in rod-mediated DA
research. Despite this, there is no consensus on
how RIT is recorded for people who surpass the
different experimental cut-off times set and
then how it is statistically assessed. To reiterate,
this systematic review found the current evi-
dence for the true diagnostic capabilities of this
instrument to be quite weak. For example, no
study specifically designed to satisfy STARD
(Standards for the Reporting of Diagnostic
accuracy studies) guidelines turned up in our
review [67, 68]. In fact, the original Jackson and
Edwards [13] report, which has more than 60
citations at the time of writing, is often widely
cited as evidence for the device being able to
‘sensitively and specifically detect early AMD’,
yet the sample sizes included were small (n = 17
per group), and consequently CIs for diagnostic
precision were wide.
Our systematic review indicates that there is
reasonably good evidence for people with dru-
sen and/or atrophic changes having impaired
slowed DA, particularly those with SDDs
[23, 24, 28, 31, 33, 36, 55–59, 69]. Most
32 Ophthalmol Ther (2021) 10:21–38
published literature on DA is characterised by
CFP, which remains the gold standard for AMD
diagnosis and grading, despite the recognised
limitations of the technique [24, 70]. This
review showed that recent studies utilised
imaging devices (such as optical coherence
tomography) to further examine the evident
structure–function relationship that has
emerged in DA research [24, 28, 31, 36, 37].
Subsequently, further relationships with AMD
macular anatomy and DA such as choroidal [23]
and retinal thickness [36] have been found,
both at and beyond the DA testing location
[24].
This systematic review identified a number
of studies which evaluated parameters of cone
adaptation in addition to or instead of rod
adaptation. This was either through direct
assessment of parameters of the cone branch of
the DA function [22, 41, 42, 44–50, 53, 54,
60, 63, 65] or by assessment of cone photostress
recovery [15, 41, 43, 51, 52, 61, 62, 64]. Whilst
Owsley et al. [48] reported a greater deficit in
rates of rod than cone adaptation in people with
AMD, other studies included in this review did
find evidence of significant delays in cone
adaptation [15, 22, 41, 42, 44, 45, 50, 63, 65].
This has been suggested to have clinical impli-
cations in light of the more rapid rate of cone
than rod sensitivity, and the resultant reduction
in the clinical testing time [45].
Our review revealed some other findings.
Only a small number of the studies directly
compared DA to a measure of visual function,
and findings were mixed [23, 26, 34, 36, 52].
Whilst lack of concordance with other measures
of visual function can be interpreted as offering
new information about the functional deficits
of the condition, this notion needs to be for-
mally tested in a prospective study. This review
highlighted the importance of controlling for
age, as it is a confounder in case–control and
other observational studies [28, 31]. We noticed
that some studies did not use an age-matched or
age-related control group, often resulting in
large differences in ages between groups
[12, 71].
The association between measurement of DA
and subjective complaints of visual dysfunction
were first reported more than 30 years ago [72].
Yet, this review highlights a surprising lack of
studies investigating the relationship between
PROMs and DA parameters. A series of
notable exceptions led to Owsley et al. [46]
developing a 32-item LLQ, which was evaluated
in some of the studies included in this review
[32, 33, 36, 46, 47]. The LLQ builds on reports
from people with AMD that visual function is
more impaired under low lighting conditions
[30, 46, 73, 74]. Interestingly, Owsley and team
found a lack of correlation between the out-
comes from the PROM and cone-mediated DA
in two separate studies [46, 47], which may be
surprising, as cone adaptation is important in
early adjustment in vision when moving from a
high to low level of luminance. Moreover, we
did not find a single study looking at how
measures of DA could be associated with people
with AMD performing real-world visually gui-
ded tasks, or surrogates of them (sometimes
referred to as performance-based tasks). Such
tasks could measure face recognition, search
performance, visuomotor control or mobility
[75–77]. For example, DA would be expected to
impact mobility in low lighting, and this could
be a promising area of research.
Our review indicates other gaps in the liter-
ature as well. Many of the studies used the
AdaptDx instrument (21 out of 48) but surpris-
ingly, there were few data on the repeatability
and reproducibility of measurements from this
device. Apart from the Flamendorf et al. [23]
study, there were no data on the practise effect
or learning effect with the task; this is surprising
given the psychophysical nature of the test.
We consider our systematic review to be
timely. The most recent prior assessment of the
literature on examination of DA in AMD was
published 14 years ago as part of a larger review
of the literature on visual function tests in AMD
[17]. We found 48 new studies published since
then on DA and photostress testing in people
with AMD that satisfied the inclusion and
exclusion criteria for our review. In addition,
new adaptometers have been introduced and
are now being used clinically. Our review and
the results reported have some limitations. First,
this review combined observations on photo-
stress testing and alternative DA procedures to
AdaptDx which differ in their experimental
Ophthalmol Ther (2021) 10:21–38 33
design. This was necessary due to the inherent
heterogeneity of DA assessment. Second, only
studies published in peer-reviewed journals
were included, and we excluded protocols and
non-English-language manuscripts. Third, we
limited our search to studies including an
evaluation of the kinetics of DA and, as such, we
did not consider studies which evaluated
thresholds in the absence of a prior photostress.
Furthermore, pachychoroid diseases have been
brought to attention as a possible explanation
for AMD pathogenesis and are thought to be
clinically separate from drusen-driven AMD
[78, 79]. As a result, DA measurement may be
different in AMD associated with pachychoroid,
a factor not considered in this systematic review
which requires further analysis.
CONCLUSION
This systematic review was the first in 14 years
to assess the growing literature in DA assess-
ment in AMD. This review highlights the vari-
ety of experimental methodology currently
used in the field. Assessment of DA is a very
promising measure of visual function, and it
may play an important role in early detection
and monitoring of AMD in clinical practice and
in experimental studies.
We have highlighted the need for further
evidence of the discriminatory power of DA
measurement to better differentiate early-stage
AMD and normative macular ageing. Further
data on repeatability, reproducibility, practice
effects and the true diagnostic precision of RIT
as recorded by AdaptDx are needed as well.
There is reasonably good evidence on how
structural abnormalities such as SDDs nega-
tively impact DA. However, more research on
the relationship between DA and VA, CS, mea-
sures from microperimetry, PROMs and perfor-
mance-based measures are required to see how
this assessment fits in with the spectrum of
measuring visual function in AMD.
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